Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1703

Sort by

Sort Order Select

Journal Articles

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Roger Belizaire, Sebastian H. J. Koochaki, Namrata D. Udeshi, Alexis Vedder, Lei Sun, Tanya Svinkina, Christina Hartigan, Marie McConkey, Veronica Kovalcik, Amanuel Bizuayehu, Caroline Stanclift, Monica Schenone, Steven A. Carr, Eric Padron, Benjamin L. Ebert

Blood (2021) 137 (16): 2209–2220.

https://doi.org/10.1182/blood.2020006528

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

Shilpa Paul, PharmD, Koji Sasaki, MD, J Michael Savoy, PharmD, Adam Dipippo, PharmD, Nadya Jammal, PharmD, Kayleigh Marx, PharmD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3810.

https://doi.org/10.1182/blood-2019-130284

Published: 2019

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Marlise Luskin, MDMS, Mark A. Murakami, MDMA,MMSc, Kristen E. Stevenson, MS, Martha Wadleigh, MD, Malgorzata McMasters, MD, Peter Winter, PhD, David M. Weinstock, MD, Richard Stone, MD, Daniel J. DeAngelo, MD PhD

Blood (2019) 134 (Supplement_1): 3879.

https://doi.org/10.1182/blood-2019-125138

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Blood (2019) 134 (Supplement_1): 3815.

https://doi.org/10.1182/blood-2019-129396

Published: 2019

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Bachar Samra, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Marina Y Konopleva, MD PhD, Rita Khouri, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Cesar Nunez, MD, Tapan M. Kadia, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3819.

https://doi.org/10.1182/blood-2019-127499

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Marcin M Machnicki, MSc, Monika Pepek, MSc, Iwona Solarska, PhD, Joanna Niesiobedzka-Krezel, MD PhD, Ilona Seferynska, MD PhD, Joanna Gora Tybor, MD PhD, Magdalena Zawada, PhD, Tomasz Sacha, MD PhD, Waldemar Sawicki, MD PhD, Ewa Wasilewska, MD PhD, Katarzyna Pruszczyk, MD, Malgorzata Rydzanicz, PhD, Rafal Ploski, MD PhD, Tomasz Skorski, MD PhD, Tomasz Stoklosa, MD PhD

Blood (2019) 134 (Supplement_1): 4148.

https://doi.org/10.1182/blood-2019-129834

Published: 2019

Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 4149.

https://doi.org/10.1182/blood-2019-122092

Published: 2019

Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Blood (2019) 134 (Supplement_1): 4150.

https://doi.org/10.1182/blood-2019-127619

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2753.

https://doi.org/10.1182/blood-2019-122017

Published: 2019

Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Blood (2019) 134 (Supplement_1): 2578.

https://doi.org/10.1182/blood-2019-125131

Published: 2019

Journal Articles

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Jeremy Chang, MD, Sherry Zhang, MD, Mojtaba Akhtari, MD

Blood (2019) 134 (Supplement_1): 2581.

https://doi.org/10.1182/blood-2019-123738

Published: 2019

NARROW

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only